Antengene's pipeline includes five clinical-stage products, ranging from Phase 1/2 to NDA stage. ATG-010 is a first-in-class selective inhibitor of nuclear export. It is approved for treatment of relapsed/refractory multiple myeloma in the U.S., and there are multiple registration studies ongoing for additional indications including diffuse large B-cell lymphoma, liposarcoma, endometrial cancer, etc. ATG-008 is a dual mTORC1/2 inhibitor in development of indications including hepatocellular carcinoma, diffuse large B-cell lymphoma, esophageal cancer, non-small cell lung cancer, etc. Two other Phase 1 and Phase 2 clinical-stage compounds, ATG-016 and ATG-019, are in clinical development for treatment of multiple cancer types, including MDS, colorectal and prostate cancers. ATG-527, a first-in-class anti-viral and anti-inflammatory compound, has completed its first-in-human trial and is in clinical development for treatment of lupus, Epstein-Barr virus related diseases, respiratory syncytial virus, etc. ATG-017 is a potent and selective small molecule extracellular signal–regulated kinases 1 and 2 (ERK1/2) inhibitor, in clinical development for multiple solid tumors.

Antengene drug discovery team is working on development of first-in-class novel products.